|
|
| | ReMogliflozin etabonate Basic information |
| Product Name: | ReMogliflozin etabonate | | Synonyms: | ReMogliflozin etabonate;ethyl [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[5-methyl-1-propan-2-yl-4-[(4-propan-2-yloxyphenyl)methyl]pyrazol-3-yl]oxyoxan-2-yl]methyl carbonate;GSK 189075;ethyl(((2R,3S,4S,5R,6S)-6-((4-(4-isopropoxybenzyl)-1-isopropyl-5-methyl-1H-pyrazol-3-yl)oxy)-3,4,5-tri(l1-oxidanyl)tetrahydro-2H-pyran-2-yl)methyl)carbonateGSK-189075;EOS-61714;UAOCLDQAQNNEAX-ABMICEGHSA-N;β-D-Glucopyranoside, 5-methyl-4-[[4-(1-methylethoxy)phenyl]methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl, 6-(ethyl carbonate);GSK 189075A | | CAS: | 442201-24-3 | | MF: | C26H38N2O9 | | MW: | 522.6 | | EINECS: | | | Product Categories: | | | Mol File: | 442201-24-3.mol |  |
| | ReMogliflozin etabonate Chemical Properties |
| Boiling point | 661.3±55.0 °C(Predicted) | | density | 1.31±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: Soluble; Methanol: Soluble | | pka | 12.58±0.70(Predicted) | | form | A solid | | color | White to off-white | | InChIKey | UAOCLDQAQNNEAX-JJJFNNNPNA-N | | SMILES | O([C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)OCC)O1)O)C1=NN(C(C)C)C(C)=C1CC1C=CC(OC(C)C)=CC=1 |&1:1,2,3,5,7,r| |
| | ReMogliflozin etabonate Usage And Synthesis |
| Uses | Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity sodium glucose cotransporter (SGLT2) inhibitor with Ki values of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate is a proagent based on benzylpyrazole glucoside and is metabolized to its active form, Remogliflozin, in the body. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models[1]. | | Definition | ChEBI: Remogliflozin etabonate is a glycoside. | | Synthesis | Synthesis of ReMogliflozin etabonate
 | | in vivo | Remogliflozin etabonate (GSK189075; 10 or 30 mg/kg; orally; twice daily for 6 weeks) significantly reduced both the FPG and GHb levels in a dosedependent manner[1].
Remogliflozin etabonate (3, 10, 30 mg/kg; orally) increases urinary glucose excretion in a dose-dependent manner. Remogliflozin etabonate dose-dependently inhibits the increase in plasma glucose after glucose loading and decreases the plasma insulin in normal rats[1].
Remogliflozin etabonate (1-10 mg/kg; orally) decreases the blood glucose and reduces the AUC0–6 h for blood glucose in a dose-dependent manner[1].
Remogliflozin etabonate (high-fat diet containing 0.01, 0.03, or 0.1% remogliflozin etabonate for 8 weeks) reduces the levels of plasma glucose, plasma insulin, and GHb in a dose-dependent manner, and it suppresses the development of hypertriglyceridemia in male GK rats (6 weeks of age)[1].
| Animal Model: | db/db mice at the age of 8 weeks[1] | | Dosage: | 10 or 30 mg/kg | | Administration: | Orally; twice daily for 6 weeks | | Result: | Significantly reduced both the fasting plasma glucose (FPG) and glycated hemoglobin (GHb) levels in a dosedependent manner.
Reduced both urine volume and urinary glucose excretion with ameliorated the hyperglycemia.
|
| | IC 50 | hSGLT2: 1.95 μM (Ki); rSGLT2: 2.14 μM (Ki); hSGLT1: 43.1 μM (Ki); rSGLT1: 8.57 μM (Ki) | | References | [1] Yoshikazu Fujimori, et al. Remogliflozin Etabonate, in a Novel Category of Selective Low-Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitors, Exhibits Antidiabetic Efficacy in Rodent Models. J Pharmacol Exp Ther. 2008 Oct;327(1):268-76. DOI:10.1124/jpet.108.140210 |
| | ReMogliflozin etabonate Preparation Products And Raw materials |
|